Role of brentuximab vedotin in the treatment of relapsed or refractory Hodgkin lymphoma

Figures & data

Figure 1 Mechanism of action of brentuximab vedotin.

Abbreviation: HRS, Hodgkin Reed Sternberg.

Table 1 Phase I experience with brentuximab vedotin

	Younes et al^Citation17	Fanale et al^Citation15
Patients (n)	45	44
HL patients	42	38
Median prior therapies (range)	3 (1–7)	3 (1–8)
Patients with prior ASCT (%)	33 (73%)	30 (68%)
Dosing schedule	0.1–3.6 mg/kg IV every 21 days	0.4–1.4 mg/kg on days 1, 8, 15, every 28 days
Tumor regression (%)	34 of 42 evaluable patients (86%)	35 of 41 evaluable patients (85%)
Objective response rate (%)	17 (40%)	24 (59%)
Complete remissions (%)	11 (26%)	14 (34%)

Abbreviations: ASCT, autologous stem cell transplantation; HL, Hodgkin lymphoma; IV, intravenously.

YounesABartlettNLLeonardJPBrentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomasN Engl J Med2010363191812182121047225

 PubMed Web of Science ®Google Scholar

FanaleMAForero-TorresARosenblattJDA phase I weekly dosing study of brentuximab vedotin in patients with relapsed/refractory CD30-positive hematologic malignanciesClin Cancer Res201218124825522080439

 PubMed Web of Science ®Google Scholar